Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes

Osteoclasts are known to contribute to joint degradation in osteoarthritis, but the specific mechanisms by which they resorb different joint compartments remain unclear. While prior research has shown that osteoclasts can degrade cartilage in vitro, the distinct resorption processes for calcified and non-calcified tissues have not been fully characterized. Established knowledge indicates that cathepsin K may play a role in these processes, but the involvement of other enzymes like matrix metalloproteinases (MMPs) and cysteine proteases has not been well defined. This gap motivated the development of a novel in vitro model to investigate osteoclast activity on different ECM substrates. The study aimed to clarify whether osteoclasts use different resorption pathways for bone and cartilage. Prior work has not yet resolved how osteoclasts adapt their function to different ECM compositions. This uncertainty drove the current investigation into osteoclast-mediated degradation of joint compartments. Understanding these processes could help identify new therapeutic targets for diseases like osteoarthritis.

This study aimed to determine how osteoclasts degrade different knee joint compartments, including calcified and non-calcified cartilage and subchondral bone. The researchers sought to identify the specific resorption mechanisms involved in each tissue type. By using a novel in vitro model, they tested whether osteoclasts employ distinct processes for bone and cartilage degradation. The study also aimed to assess the role of acidification and proteolytic enzymes in these processes. The motivation for this work stems from the need to better understand osteoarthritis pathology at the cellular level. The researchers wanted to explore whether osteoclasts can degrade cartilage independently of bone resorption mechanisms. They also aimed to evaluate the potential of their model for drug and biomarker development. This work could help clarify how osteoclast activity contributes to joint degeneration in rheumatic diseases.

The researchers used a novel in vitro model to culture mature human osteoclasts on extracellular matrix (ECM) samples isolated from bovine knees. The ECM samples included articular cartilage, cortical bone, and an osteochondral junction mixture. Osteoclast cultures were exposed to inhibitors of specific enzymes, including E-64 (a cysteine protease inhibitor), GM6001 (an MMP inhibitor), and diphyllin (a V-ATPase inhibitor). Biomarkers of degradation were measured in the culture supernatants. These included calcium, C-terminal type I collagen (CTX-I), and C2M for cartilage. Background samples without osteoclasts were used as controls. The levels of biomarkers were normalized to vehicle-treated conditions and analyzed using statistical tests like ANOVA with post hoc analyses. The study compared the effects of each inhibitor on different ECM substrates. This approach allowed the researchers to assess the relative contributions of acidification and proteolytic enzymes to osteoclast-mediated resorption.

Osteochondral CTX-I release was significantly inhibited by E-64, GM6001, and their combination, with the combined treatment reducing release to 4% of the vehicle condition. Bone CTX-I release was similarly inhibited by these inhibitors. Diphyllin also reduced osteochondral CTX-I release to 48% of the vehicle, though less effectively than on bone. Osteochondral C2M release was inhibited by E-64 and GM6001, with complete inhibition when both were used together. Cartilage C2M release was not significantly affected by E-64 but was completely abrogated by GM6001. These findings suggest that both MMPs and cysteine proteases are involved in calcified cartilage resorption. Acidification was less critical for cartilage degradation than for bone. The results indicate that osteoclasts use different resorption processes for different joint compartments. The study provides evidence that calcified cartilage degradation is mediated by proteolytic enzymes rather than acidification.

The authors concluded that osteoclasts can resorb calcified cartilage independently of acidification, relying instead on proteolytic enzymes like MMPs and cysteine proteases. They demonstrated that different ECM substrates require distinct resorption mechanisms. The study supports the idea that osteoclasts use both MMP-mediated and cysteine protease-mediated pathways for calcified cartilage degradation. The findings suggest that osteoclast functionality is highly substrate-dependent. The novel culture system developed in this study has potential for drug and biomarker development in rheumatic diseases. The researchers propose that pathological osteoclast activity in specific joint compartments may contribute to osteoarthritis progression. Their model could help identify new therapeutic targets for diseases like osteoarthritis. The study highlights the importance of understanding osteoclast-mediated degradation in joint tissues.